Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
Trial · NCT02915523
Adverse events720
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 720
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (3 mg) | 2 | 6 | |
| other | Nausea | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (5 mg) | 6 | 8 | |
| other | Nausea | Gastrointestinal disorders | Phase 2: Avelumab + Placebo | 15 | 40 | |
| other | Nausea | Gastrointestinal disorders | Phase 2: Avelumab + Entinostat | 37 | 85 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (3 mg) | 3 | 6 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (5 mg) | 2 | 8 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase 2: Avelumab + Placebo | 11 | 40 | |
| other | Diarrhoea | Gastrointestinal disorders | Phase 2: Avelumab + Entinostat | 34 | 85 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (3 mg) | 2 | 6 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (5 mg) | 1 | 8 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2: Avelumab + Placebo | 12 | 40 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2: Avelumab + Entinostat | 28 | 85 | |
| other | Vomiting | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (3 mg) | 1 | 6 | |
| other | Vomiting | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (5 mg) | 2 | 8 | |
| other | Vomiting | Gastrointestinal disorders | Phase 2: Avelumab + Placebo | 11 | 40 | |
| other | Vomiting | Gastrointestinal disorders | Phase 2: Avelumab + Entinostat | 23 | 85 | |
| other | Constipation | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (3 mg) | 0 | 6 | |
| other | Constipation | Gastrointestinal disorders | Phase 1B: Avelumab + Entinostat (5 mg) | 4 | 8 | |
| other | Constipation | Gastrointestinal disorders | Phase 2: Avelumab + Placebo | 11 | 40 | |
| other | Constipation | Gastrointestinal disorders | Phase 2: Avelumab + Entinostat | 24 | 85 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02915523/events